Orexigen Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Orexigen Therapeutics, Inc.
Cardio Catch-Up: Arga, HeartPoint Plan First-In-Human Trials Of Novel Devices; Medtronic And Edwards Announce Product Launches, And More
The second half of summer is usually a slow time for news about cardiac technology innovations because there are not many major conferences. But there was still plenty of innovation news coming from both small and big cardiovascular device companies in July and August.
Plus deals involving Glaukos/iVeena, Daré/Hennepin Life Sciences, Prevail/Lacerta, Chugai/Noile-Immune, Horizon/Q32, EpiAxis/Peptilogics and more.
Public Company Financings: Theravance sold its 85% interest in Trelegy royalties from GSK and Innoviva sold its 15% interest for up to $1.8bn in total. Also, ProKidney grossed $597m from its SPAC merger, Pliant raised $200m in a post-Phase IIa offering and Marinus earned $110m in a PRV sale.
The Finnish group has concluded an extensive search to partner its first-in-class CYP11A1 inhibitor, banking an impressive $290m upfront fee for the Phase II drug which is being evaluated for metastatic castration-resistant prostate cancer.
- Other Names / Subsidiaries
- Orexigen Therapeutics Ireland Ltd.